We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




New Test Accurately Detects Latent HIV

By LabMedica International staff writers
Posted on 14 Jun 2017
The ability of the human immunodeficiency virus (HIV) to lie dormant in a "reservoir" of CD4 cells has been the main obstacle to finding a cure; once a patient starts antiretroviral therapy, it becomes very important to measure the level of viremia, and whether the virus can replicate.

Most tests available for detecting the virus are not very cost effective and take a lot of time. More...
The most widely available test at the moment is the "quantitative viral outgrowth assay" (Q-VOA), but it requires large amounts of blood, is very labor intensive, and is quite expensive and additionally, the Q-VOA may also underestimate the amount of virus left.

Scientists at the University of Pittsburgh (PA, USA) and their colleagues developed a sensitive assay that can accurately and rapidly quantify inducible, replication-competent latent HIV-1 from resting CD4+ T cells, which is essential for HIV-1 eradication studies. The developed test is called TZA and it works by detecting a gene that is turned on only when replicating HIV is present, thereby flagging the virus for technicians to quantify.

The TZA test produces results in one week compared to the two weeks needed using the Q-VOA, and at a third of the cost. The TZA test also may be useful for quantification of replication-competent HIV-1 in the pediatric population, because of its low cell requirement, as well as in the lymph nodes and tissues where the virus persists. The assay has several advantages over existing technology in that it is sensitive; requires only a small blood volume; is faster, less labor intensive, and less expensive; and can be readily adapted into a high-throughput format. Using this assay, the authors show that the size of the inducible latent HIV-1 reservoir in aviremic participants on therapy is approximately 70-fold larger than previous estimates.

Phalguni Gupta, PhD, a professor and senior author of the study, said, “Using this test, we demonstrated that asymptomatic patients on antiretroviral therapy carry a much larger HIV reservoir than previous estimates, as much as 70 times what the Q-VOA test was detecting. Because these tests have different ways to measure HIV that is capable of replicating, it is likely beneficial to have both available as scientists strive toward a cure." The study was published on May 29, 2017, in the journal Nature Medicine.

Related Links:
University of Pittsburgh


New
Gold Member
Collection and Transport System
PurSafe Plus®
Portable Electronic Pipette
Mini 96
New
ESR Analyzer
TEST1 2.0
New
Laboratory Software
ArtelWare
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Immunology

view channel
Image: The VENTANA HER2 (4B5) test is now CE-IVDR approved (Photo courtesy of Roche)

Companion Diagnostic Test Identifies HER2-Ultralow Breast Cancer and Biliary Tract Cancer Patients

Breast cancer is the most common cancer in Europe, with more than 564,000 new cases and 145,000 deaths annually. Metastatic breast cancer is rising in younger populations and remains the leading cause... Read more

Technology

view channel
Image: Conceptual design of the CORAL capsule for microbial sampling in the small intestine (H. Mohammed et al., Device (2025). DOI: 10.1016/j.device.2025.100904)

Coral-Inspired Capsule Samples Hidden Bacteria from Small Intestine

The gut microbiome has been linked to conditions ranging from immune disorders to mental health, yet conventional stool tests often fail to capture bacterial populations in the small intestine.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.